Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer to Receive 2.66 Billion Pounds From Haleon
Drug giant Pfizer sells $3.3 bln stake in Sensodyne-maker Haleon
Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer to Receive 2.66 Billion Pounds From Haleon in Share Deal
Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical company sold 640 million ordinary shares in British consumer-healthcare business Haleon at 380 pence a share.
Drug giant Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon
Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.
Pfizer Sells $3.26B Stake in Haleon
Pfizer Inc. ($PFE) has sold its stake worth $3.26 billion in UK-based consumer healthcare company Haleon PLC ($GB:HLN). With this transaction,
Pfizer cuts Haleon stake in $3.3B share sale
Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual divestment strategy. Read more here.
Pfizer to sell about $3.25 billion stake in Sensodyne-maker Haleon, bookrunner says
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
Haleon buys back £230m of its shares as Pfizer sells down stake
Haleon said Pfizer's stake was expected to fall to 15 per cent from 22.6 per cent. Haleon shares fell 0.25 per cent or 1.00p to 391.90p, having risen around 15 per cent in the las
BioSpace
9h
Bayer, J&J and Pfizer to Lay Off Nearly 500 Combined Employees
Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland ...
FiercePharma
1d
Amid large cost-cutting drive, Pfizer plans manufacturing layoffs in Ireland
No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...
9h
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, ...
BioSpace
10h
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
FiercePharma
5h
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...
Medscape
2d
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
6d
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
1d
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
1d
on MSN
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Haleon
Oxbryta
New York Stock Exchange
sickle cell disease
Ireland
Feedback